Cocrystal Pharma Reports Results From Single-Ascending Dose Cohorts Of Phase 1 Study With CDI-988, Its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
Portfolio Pulse from Benzinga Newsdesk
Cocrystal Pharma, Inc. (NASDAQ:COCP) reported favorable safety and tolerability results from the single-ascending dose cohorts of its Phase 1 study with CDI-988, an oral pan-viral protease inhibitor targeting norovirus and coronaviruses.
July 18, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cocrystal Pharma reported positive safety and tolerability results from its Phase 1 study of CDI-988, an oral pan-viral protease inhibitor. This could boost investor confidence in the company's drug development pipeline.
The positive Phase 1 results for CDI-988 indicate that the drug is safe and well-tolerated, which is a crucial milestone in drug development. This news is likely to boost investor confidence and positively impact COCP's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100